Login to Your Account



Apogenix Lands $12.5M For CD95 Ligand Inhibitor

By Cormac Sheridan
BioWorld Today Correspondent

Friday, January 6, 2012

Apogenix AG took in €7.5 million (US$9.6 million) in new investment, plus a further €2.3 million in government funding, to continue clinical development of its lead molecule, APG101, and to fund associated biomarker research.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription